Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Industry Proposes Incentive To Develop New Antimicrobials

EFPIA Urges Care Over Definition Of ‘Unmet Medical Need’

Executive Summary

With proposals for an overhaul of the EU medicines legislation due at the end of this year, EFPIA has published its formal response to the European Commission’s consultation with suggestions for facilitating new antibiotic development, testing new regulatory approaches to novel medicines, and tackling medicine shortages.

You may also be interested in...



AMR: UK’s Subscription Scheme ‘One Way Forward,’ But New Economic Models Needed

Stimulating the development of novel antibiotic drugs and diagnostics will require new funding models as part of the broader “push and pull” incentives strategy, says the director of health & life sciences at Innovate UK.

EU Plans To Trial Antimicrobial Voucher Scheme For 15 Years

Proposals for an EU voucher that would encourage the development of “game-changing” antimicrobials are accompanied by plans for procurement mechanisms to guarantee revenues for companies regardless of sales volumes. But one law firm said the conditions attached to the voucher were so strict that the scheme appeared “unworkable.”

‘Regulatory Sandbox’ In EU's Sights For Innovative Drug Development & Approval

The European Commission’s vision for a more agile and streamlined drug development and assessment framework includes the use of controlled regulatory environments for testing innovative new drugs and technologies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel